(Times of Israel) Shoshanna Solomon - Israel's Pluristem Therapeutics Inc., a developer of placenta-based cell therapy products, said Tuesday that it will receive an investment of $30 million from China-based Innovative Medical Management Co. to support the Israeli company's late-stage stem cell trials. Pluristem's patented Placental eXpanded (PLX) cell products release a range of therapeutic proteins in response to inflammation, ischemia, hematological and radiation damage. Pluristem processes its cells from placentas from women undergoing caesarean section births. The placenta contains cells which stimulate the body's own mechanisms to heal damaged tissues. Placental cells do not elicit an immunological response from the body and can be used without requiring tissue-matching.
2016-10-28 00:00:00Full ArticleBACK Visit the Daily Alert Archive